Opendata, web and dolomites

SweetAim SIGNED

Selective glycoimmuno-targeting for cancer therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SweetAim project word cloud

Explore the words cloud of the SweetAim project. It provides you a very rough idea of what is the project "SweetAim" about.

glyco    vitro    acquired    potency    carbohydrate    human    universal    specificity    clinical    sweet    refined    therapy    appears    passive    engineer    poor    foreign    death    diseases    diet    carcinomas    nanotechnology    altered    line    glycoconjugates    red    subsequently    moieties    interdisciplinary    boundaries    recognition    theranostics    glycosciences    affinity    mostly    primary    arms    basic    immunogenicity    edge    scarce    ing    sweetaim    diagnostic    discovery    generate    treatment    alternative    personalized    platform    accumulating    antibodies    tools    regimes    innovative    largely    immunogenic    meat    crossing    desired    cancer    carbohydrates    mediated    immune    antigen    chronic    moiety    inflammation    regarding    cutting    unveiling    self    cell    cells    hallmarks    immunology    dietary    potent    polyclonal    autoantibodies    diverse    theranostic    shown    antigens    fundamental    conventional    glycosylation    xeno    technologies    immunotherapy    reprogramming    optimized    achievements    elusive    active    unlock    screen    sugar    engineering    tumor    became    surface    groundbreaking    therapeutic    vivo   

Project "SweetAim" data sheet

The following table provides information about the project.

Coordinator
TEL AVIV UNIVERSITY 

Organization address
address: RAMAT AVIV
city: TEL AVIV
postcode: 69978
website: http://www.tau.ac.il/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://www3.tau.ac.il/karavani/
 Total cost 1˙479˙995 €
 EC max contribution 1˙479˙995 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-STG
 Funding Scheme ERC-STG
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2021-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TEL AVIV UNIVERSITY IL (TEL AVIV) coordinator 1˙479˙995.00

Map

 Project objective

Immunotherapy recently became an important alternative to conventional treatment regimes, yet cancer remains a universal leading cause of death. Thus, novel cancer theranostic approaches are still much desired. Although altered cell surface glycosylation is one of the hallmarks of cancer, targeting this ‘sweet aim’ for cancer therapy has been elusive, largely due to carbohydrates poor immunogenicity and the low affinity of antibodies against them. A red meat-derived carbohydrate antigen is a novel immunogenic moiety providing a key to unlock the theranostic potential of tumor-associated carbohydrate antigens. This foreign non-human sugar can be acquired only through the diet and subsequently appears on diverse cell surface glycoconjugates as ‘self’, accumulating mostly on carcinomas, and resulting in a polyclonal xeno-autoantibodies response. I have shown that such antibodies have both diagnostic and therapeutic potential, although basic understanding of their specificity and potency is scarce. The primary objective of this proposal is to design a novel personalized cancer therapeutic approach based on xeno-autoantibodies against the dietary sugar antigen. We propose an innovative interdisciplinary approach crossing the boundaries of cancer research, glycosciences, immunology and nanotechnology, with cutting-edge technologies, to design, engineer, screen and fully investigate potent targeting of ‘SweetAim’ moieties. Our discovery line is based on a two-arms platform to generate optimized antibodies for passive/active therapy, together with refined tumor cells through glyco-engineering/reprogramming for unveiling novel theranostics, finally evaluated both in vitro and in vivo. I expect our groundbreaking achievements will lead to promising new clinical tools, particularly for cancer, but also for other chronic inflammation-mediated diseases. Importantly, it will establish fundamental new concepts regarding carbohydrate recognition and response by the immune system.

 Publications

year authors and title journal last update
List of publications.
2018 Madhuri Gade, Catherine Alex, Shani Leviatan Ben-Arye, João T. Monteiro, Sharon Yehuda, Bernd Lepenies, Vered Padler-Karavani, Raghavendra Kikkeri
Microarray Analysis of Oligosaccharide-Mediated Multivalent Carbohydrate-Protein Interactions and Their Heterogeneity
published pages: 1170-1177, ISSN: 1439-4227, DOI: 10.1002/cbic.201800037
ChemBioChem 19/11 2019-08-29
2019 Shani Leviatan Ben-Arye, Christoph Schneider, Hai Yu, Salam Bashir, Xi Chen, Stephan von Gunten, Vered Padler-Karavani
Differential Recognition of Diet-Derived Neu5Gc-Neoantigens on Glycan Microarrays by Carbohydrate-Specific Pooled Human IgG and IgA Antibodies
published pages: 1565-1574, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.9b00273
Bioconjugate Chemistry 30/5 2019-08-29
2019 Eliran Moshe Reuven, Shani Leviatan Ben-Arye, Hai Yu, Roberto Duchi, Andrea Perota, Sophie Conchon, Shirley Bachar Abramovitch, Jean-Paul Soulillou, Cesare Galli, Xi Chen, Vered Padler-Karavani
Biomimetic Glyconanoparticle Vaccine for Cancer Immunotherapy
published pages: 2936-2947, ISSN: 1936-0851, DOI: 10.1021/acsnano.8b07241
ACS Nano 13/3 2019-08-29
2018 Salam Bashir, Shani Leviatan Ben Arye, Eliran Moshe Reuven, Hai Yu, Cristina Costa, Manuel Galiñanes, Tomaso Bottio, Xi Chen, Vered Padler-Karavani
Presentation Mode of Glycans Affect Recognition of Human Serum anti-Neu5Gc IgG Antibodies
published pages: 161-168, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.8b00817
Bioconjugate Chemistry 30/1 2019-08-29
2019 Preston S. K. Ng, Christopher J. Day, John M. Atack, Lauren E. Hartley-Tassell, Linda E. Winter, Tal Marshanski, Vered Padler-Karavani, Ajit Varki, Stephen J. Barenkamp, Michael A. Apicella, Michael P. Jennings
Nontypeable Haemophilus influenzae Has Evolved Preferential Use of N- Acetylneuraminic Acid as a Host Adaptation
published pages: , ISSN: 2150-7511, DOI: 10.1128/mbio.00422-19
mBio 10/3 2019-08-29
2018 Chethan D. Shanthamurthy, Prashant Jain, Sharon Yehuda, João T. Monteiro, Shani Leviatan Ben-Arye, Balamurugan Subramani, Bernd Lepenies, Vered Padler-Karavani, Raghavendra Kikkeri
ABO Antigens Active Tri- and Disaccharides Microarray to Evaluate C-type Lectin Receptor Binding Preferences
published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-018-24333-y
Scientific Reports 8/1 2019-06-13
2018 Anu Paul, Vered Padler-Karavani
Evolution of sialic acids: Implications in xenotransplant biology
published pages: e12424, ISSN: 0908-665X, DOI: 10.1111/xen.12424
Xenotransplantation 2019-06-13
2017 Ron Amon, Shani Leviatan Ben-Arye, Limor Engler, Hai Yu, Noha Lim, Ludmilla Le Berre, Kristina M. Harris, Mario R. Ehlers, Stephen E. Gitelman, Xi Chen, Jean-Paul Soulillou, Vered Padler-Karavani
Glycan microarray reveal induced IgGs repertoire shift against a dietary carbohydrate in response to rabbit anti-human thymocyte therapy
published pages: , ISSN: 1949-2553, DOI: 10.18632/oncotarget.23096
Oncotarget 8/68 2019-04-18
2018 Ron Amon, Oliver C. Grant, Shani Leviatan Ben-Arye, Spandana Makeneni, Anita K. Nivedha, Tal Marshanski, Christoffer Norn, Hai Yu, John N. Glushka, Sarel J. Fleishman, Xi Chen, Robert J. Woods, Vered Padler-Karavani
A combined computational-experimental approach to define the structural origin of antibody recognition of sialyl-Tn, a tumor-associated carbohydrate antigen
published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-018-29209-9
Scientific Reports 8/1 2019-04-18
2016 Vered Padler-Karavani
Glycan Microarray Reveal the Sweet Side of Cancer Vaccines
published pages: 1446-1447, ISSN: 2451-9456, DOI: 10.1016/j.chembiol.2016.12.002
Cell Chemical Biology 23/12 2019-08-29

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SWEETAIM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SWEETAIM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

VictPart (2019)

Righting Victim Participation in Transitional Justice

Read More  

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

KEYNESGROWTH (2020)

Economic Fluctuations, Productivity Growth and Stabilization Policies: A Keynesian Growth Perspective

Read More